Journal of Clinical & Experimental Immunology(JCEI)
ISSN: 2475-6296 | DOI: 10.33140/JCEI
Impact Factor: 1.9
Researchers and authors can directly submit their manuscript online through this link Online Manuscript Submission.
Side Effect Driven Conversion to Belatacept for Kidney Transplant Recipients in a Clinical Setting
Abstract
Elizabeth Cohen, Richard N Formica, and Ramesh K Batra
Maintenance immunosuppression after kidney transplantation is critical to graft and patient survival. However, the optimal immunosuppressive medication may differ for patients based on adverse effects. Here we report one-year outcomes of 73 kidney transplant patients converted from tacrolimus to belatacept because of adverse effects at least 90 days after transplant.